SCHEMBL3493078

SCHEMBL3493078

COc1ccc(Cc2nc3sc(C(=O)O)c(C)c3c(=O)[nH]2)cc1Br

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RNASEH1 O60930 1/20 0.64
MAPT P10636 7/20 0.52
ALDH1A1 P00352 9/20 0.51
KMT2A Q03164 8/20 0.51
KDM4E B2RXH2 2/20 0.51
GAA P10253 2/20 0.51
KDM4C Q9H3R0 1/20 0.51
MEN1 O00255 5/20 0.49
PSMD14 O00487 1/20 0.49
MAPK1 P28482 1/20 0.49
TDP1 Q9NUW8 4/20 0.48
L3MBTL1 Q9Y468 3/20 0.48
POLB P06746 5/20 0.48
USP2 O75604 1/20 0.48
THRB P10828 1/20 0.48
APOBEC3A P31941 1/20 0.48
APOBEC3G Q9HC16 1/20 0.48
HPGD P15428 1/20 0.45
APEX1 P27695 1/20 0.45
RECQL P46063 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3493912 0.91 MAPT (0.55) RNASEH1MAPTALDH1A1KMT2AKDM4E
SCHEMBL4510671 0.89 KMT2A (0.57) RNASEH1MAPTALDH1A1KMT2AKDM4E
SCHEMBL3491632 0.85 MAPT (0.53) RNASEH1MAPTALDH1A1KMT2AKDM4E
SCHEMBL3494432 0.84 KMT2A (0.60) MAPTALDH1A1KMT2AKDM4EGAA
SCHEMBL3490709 0.83 ALDH1A1 (0.61) MAPTALDH1A1KMT2AKDM4EGAA
SCHEMBL3492382 0.82 KMT2A (0.59) MAPTALDH1A1KMT2AKDM4EGAA
SCHEMBL3491464 0.81 KMT2A (0.60) MAPTALDH1A1KMT2AKDM4EGAA
SCHEMBL3490694 0.81 MAPT (0.65) MAPTALDH1A1KMT2AKDM4EGAA
SCHEMBL3491611 0.81 KMT2A (0.56) MAPTALDH1A1KMT2AKDM4EGAA
SCHEMBL3492123 0.80 MAPT (0.57) MAPTALDH1A1KMT2AKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10870656-B2 Methods for treatment of heart failure CARDURION PHARMACEUTICALS, LLC (US) 2020-12-22 US disclosed
US-20190211028-A1 METHODS FOR TREATMENT OF HEART FAILURE CARDURION PHARMACEUTICALS LLC (US) 2019-07-11 US disclosed
EP-1908765-B1 THIENOPYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2014-10-22 EP disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20100113484-A1 TREATING AGENT OF UROPATHY ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-05-06 US disclosed
EP-2123301-A1 THERAPEUTIC AGENT FOR URINARY TRACT DISEASE ASKA Pharmaceutical Co., Ltd. (JP) 2009-11-25 EP disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113484-A1 TREATING AGENT OF UROPATHY BPHL, PDE12, UROD RNASEH1 974/4885MAPT 1324/4885ALDH1A1 762/4885
US-10870656-B2 Methods for treatment of heart failure TNNT2, TNNI3, TNNC1 RNASEH1 1001/4885MAPT 4634/4885ALDH1A1 748/4885
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 RNASEH1 813/4885MAPT 1619/4885ALDH1A1 2303/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 RNASEH1 813/4885MAPT 1619/4885ALDH1A1 2303/4885
US-20190211028-A1 METHODS FOR TREATMENT OF HEART FAILURE TNNT2, TNNI3, TNNC1 RNASEH1 1001/4885MAPT 4634/4885ALDH1A1 748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.